Moreover, the decreased insulin concentrations observed with SGLT2 inhibitors administration, due to reduced glucose levels and to improvement in insulin resistance, could result in a redistribution of potassium out of the cells, thus increasing serum levels (Figure 4). Here, SLC5A2 is linked to Insulin resistance.